Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Aktis Oncology, Inc.NASDAQ: AKTS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents of $371.63M in Q1 FY2026
Q1 FY2026 cash & equivalents was $371.63M. Over 3 fiscal years it compounded at -33.5% a year.
Context
- Cash & equivalents amounted to 64.4% of total assets at the end of Q1 FY2026.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 37.78M USD
- Year-over-year change
- +1.7%
- 3-year CAGR
- -33.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.78M | +1.7% |
| FY2024 | 2024-12-31 | 37.16M | +25.9% |
| FY2023 | 2023-12-31 | 29.51M | -77.1% |
| FY2022 | 2022-12-31 | 128.6M | — |
Cash & Equivalents vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 cash & equivalents of $371.63M is the 3rd highest of the 6 companies compared; the peer median is $212.84M.
- Cash & equivalents amounts to 64.4% of total assets for AKTS, versus a peer median of 42.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $559.47M | -29.4% | +22.8% | 85.8% | |
| Mar 2026 | $452.68M | -5.1% | +5.1% | 42.2% | |
| Mar 2026 | $371.63M | — | -33.5% | 64.4% | |
| Sep 2026 | $212.84M | -21.9% | +218.0% | 42.1% | |
| Mar 2026 | $84.79M | +121.8% | -21.2% | 61.6% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Peer median (excluding AKTS) | $212.84M | -21.9% | +5.1% | 42.2% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.